In last trading session, Sangamo Therapeutics, Inc. (NASDAQ:SGMO) saw 1,079,835 shares changing hands with its beta currently measuring 2.07. Company’s recent per share price level of $11.16 trading at -$0.1 or -0.89% at ring of the bell on the day assigns it a market valuation of $1.57 Billion. That closing price of SGMO’s stock is at a discount of -18.28% from its 52-week high price of $13.2 and is indicating a premium of 56.9% from its 52-week low price of $4.81. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.39 Million shares which gives us an average trading volume of 1.62 Million if we extend that period to 3-months.
For Sangamo Therapeutics, Inc. (SGMO), analysts’ consensus is at an average recommendation of Overweight while assigning it a mean rating of 2.1. Splitting up the data highlights that, out of 10 analysts covering the stock, none rated the stock as a Sell while none recommended an Overweight rating for the stock. 3 suggested the stock as a Hold whereas 7 see the stock as a Buy. None analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.24 in the current quarter.
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) trade information
In the face of being in the red today for losing -0.89%, in the last five days SGMO remained trading in the green while hitting it’s week-highest on Wednesday, Oct 14 when the stock touched $11.61- price level, adding 3.88% to its value on the day. Sangamo Therapeutics, Inc.’s shares saw a change of 33.33% in year-to-date performance and have moved 12.84% in past 5-day. Sangamo Therapeutics, Inc. (NASDAQ:SGMO) showed a performance of 4.59% in past 30-days. Number of shares sold short was 21.35 Million shares which calculate 13.18 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $20.25 to the stock, which implies a rise of 81.45% to its current value. Analysts have been projecting $11 as a low price target for the stock while placing it at a high target of $36. It follows that stock’s current price would jump +222.58% in reaching the projected high whereas dropping to the targeted low would mean a loss of -1.43% for stock’s current value.
Sangamo Therapeutics, Inc. (SGMO) estimates and forecasts
9 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $26.55 Million for the same. And 9 analysts are in estimates of company making revenue of $28.56 Million in the next quarter that will end in December 01, 2020. Company posted $12.16 Million and $54.85 Million of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to grow by 118.3% while estimating it to be -47.9% for the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -16.6% during past 5 years. In 2020, company’s earnings growth rate is likely to be around -20.4% while estimates for its earnings growth in next 5 years are of 0%
Sangamo Therapeutics, Inc. (NASDAQ:SGMO)’s Major holders
Insiders are in possession of 21.57% of company’s total shares while institution are holding 68.85% percent of that, with stock having share float percentage of 87.78%. Investors also watch the number of corporate investors in a company very closely, which is 263 institutions for Sangamo Therapeutics, Inc. that are currently holding shares of the company. Blackrock Inc. is the top institutional holder at SGMO for having 10.35 Million shares of worth $92.7 Million. And as of June 29, 2020, it was holding 7.34% of the company’s outstanding shares.
The second largest institutional holder is Vanguard Group, Inc. (The), which was holding about 8.47 Million shares on June 29, 2020. The number of shares represents firm’s hold over 6.01% of outstanding shares, having a total worth of $75.91 Million.
On the other hand, SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of August 30, 2020, the former fund manager was holding 4196949 shares of worth $46.31 Million or 2.98% of the total outstanding shares. The later fund manager was in possession of 3.29 Million shares on June 29, 2020, making its stake of worth around $29.52 Million in the company or a holder of 2.34% of company’s stock.